Executive Chairman
Mr. Klemp is a serial entrepreneur with multiple successful exits through his career. Most recently, he was Chief Executive Officer of Soliton, Inc., a medical device company he co-founded, took public on Nasdaq in 2018 and which was acquired by AbbVie in 2021 for approximately $550 Million. Mr. Klemp joined Autonomix in January 2022 as Executive Chairman.
Additionally, Mr. Klemp is a Co-Founder of Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, and has served as its Chairman of the Board and Chief Executive Officer since July 2015 and as President since August 2017. From November 2011 to December 2020, Mr. Klemp served as Chief Executive Officer and then Executive Chairman on the Board of Directors of Soliton. Prior to Soliton, Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch.
Additionally, from 1987 to 2000, Mr. Klemp served as Chief Executive Officer and Chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America’s Fastest Growing Companies.
Executive Vice Chairman
Ms. Bisson is a seasoned Life Sciences and MedTech executive with a proven track record. She has executed multiple successful IPOs and exits, including her previous role as Chief Financial Officer of Soliton, which was acquired by AbbVie in 2021 for approximately $550 Million. Ms. Bisson joined Autonomix Medical in July 2023 and served as Chief Executive Officer and Director until June 2024. From January 2015 until June 2022, Ms. Bisson served as Chief Financial Officer of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics.
Prior to joining Soliton, Ms. Bisson worked as a financial and business development consultant as a shareholder in Condon & Company, PC, from 2009 through December 2014, where she advised a number of life science companies. From 2005 to 2009, Ms. Bisson served as the Chief Financial Officer and Vice President of Operations for Zeno Corporation, a medical device company focused on new technology in the aesthetics area. Ms. Bisson previously served as the Chief Financial Officer of Gulfstream Trading, Ltd., an international oil trading organization, from 2001 to 2005. From 1995 to 2001, Ms. Bisson held various positions with Drypers Corporation, a publicly traded multinational consumer products company, where she ultimately held the title of Vice President of Integrated Solutions and oversaw accounting, information technology and logistics for the U.S. operation.
Ms. Bisson began her career at Arthur Andersen, LLP as an auditor focused on consumer products companies. Ms. Bisson also serves as an advisor to Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of oncology drug candidates. Ms. Bisson is a Certified Public Accountant and holds a B.A. degree in Accounting from Baylor University.
Mr. Foster joined us in January 2022 as a director. Mr. Foster has served as the Chief Financial Officer and Executive Vice President of Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, since August 2016. Mr. Foster brings more than 30 years in financial experience holding a variety of executive and senior financial positions with public, private, start-up to large corporate and international companies.
From February 2012 to August 2016, Mr. Foster served as Chief Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry. From May 2011 to January 2012, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG. Prior to that Mr. Foster served in various C-suite capacities with public and private companies with his start beginning as Manager at Deloitte & Touche, LLP. Mr. Foster served on the Board of Financial Institutions for the State of South Carolina from 2006 to 2012 and from June 2018 until December 2021 served on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, where he was the Chairman of the Audit and Compensation Committees and the past Chairman of the Nominating & Governance Committee. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc.
Since June 2021, Mr. Foster has served on the Board of Directors of Volcon, Inc. where he is the past Chairman and current member of the Audit Committee, a member of the Nominating & Governance Committee and is the Chairman of the Compensation Committee. Mr. Foster is a Certified Public Accountant (South Carolina) and holds the designation of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting from Clemson University in 1985. We believe that Mr. Foster’s extensive experience in the medical field provides him with the qualifications to serve as a director.
Mr. Robins was a co-founder of our company and has served as a director since February 2022. Mr. Robins is also a founder and board member of LifeLens that is currently developing on the body sensing devices. Since 2013, Mr. Robins has served as co-CEO of DavosPharma, a privately held corporation that focuses on supporting biotechnology and medical device companies with manufacturing their products for clinical trials and commercialization.
He received his BS in Engineering Chemistry from Queen’s University in Kingston, Ontario and a MS in Chemical Engineering from Syracuse University. Mr. Robins has a significant background in taking medical devices and drugs from clinical trials to commercialization and FDA approvals.
We believe that Mr. Robins’ extensive experience in medical device development provides him with the qualifications to serve as a director.
Dr. Capelli currently works at AbbVie as the Scientific Officer & Medical Device Advisor/Soliton for Allergan Aesthetics R&D Surgical Devices. Prior to being acquired by AbbVie in December 2021, he was the Vice Chairman of the Board, Chief Science Officer and Co-founder for Soliton, Inc., a medical device company that was commercializing RESONIC™ for the dermatologic esthetics marketplace based on its Rapid Acoustic Pulse (“RAP”) technology. Dr. Capelli is the lead inventor of Soliton’s RAP technology.
A graduate of Massachusetts Institute of Technology (“MIT”) with a Bachelor of Science degree in Mechanical Engineering, Dr. Capelli earned his MD from the University of Wisconsin Medical School and maintains a medical license in the State of Wisconsin. As a result of his scientific work since graduating from MIT, Dr. Capelli holds over 100 issued patents and patent applications worldwide. These patents served as the basis for the creation of five companies having a total market capitalization greater than $36 billion. As a businessman, Dr. Capelli has been directly involved in the start-up of numerous venture-capital backed biomedical company ventures.
We believe that Dr. Capelli’s extensive experience in medical device development provides him with the qualifications to serve as a director.
Autonomix Medical, Inc.
21 Waterway Ave, Suite 300
The Woodlands, TX 77380
LEGAL DISCLAIMER
This presentation (the “presentation”) has been prepared for use by Autonomix Medical, Inc. (“Autonomix”) in connection with their proposed offering. This presentation is for information purposes only and is being provided to assist interested parties in making their own evaluation with respect to a potential investment, and for no other purpose. This presentation may not be reproduced or redistributed, in whole or in part, without the prior written consent of Autonomix. Autonomix does not make any representation or warranty as to the accuracy or completeness of the information contained in this presentation. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in connection with the proposed offering and is not intended to form the basis of any investment decision. You should consult your own legal, regulatory, tax, business, financial and accounting advisors to the extent you deem necessary and must make your own investment decision and perform your own independent investigation and analysis of an investment in the transactions contemplated in this presentation.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) NOR ANY STATE OR TERRITORIAL SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE.
FORWARD-LOOKING STATEMENTS
This presentation may include ‘’forward-looking statements.‘’ To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Autonomix Medicial, Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
USE OF DATA
The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. Autonomix assumes no obligation to update the information in this presentation.
Autonomix is committed to protecting your privacy. This Privacy Policy outlines our practices concerning the collection, use, and protection of your personal information when you visit our website or use our services.
1. Information We Collect
We may collect personal information that you voluntarily provide to us, including but not limited to:
We may also collect non-personal information, such as:
2. How We Use Your Information
We may use your personal information for various purposes, including but not limited to:
3. Cookies and Tracking Technologies
We use cookies and similar tracking technologies to collect information about your browsing behavior on our website. You can manage your cookie preferences through your browser settings.
4. Disclosure of Your Information
We may share your personal information with third parties under the following circumstances:
5. Your Rights
You have the right to:
6. Data Security
We take reasonable measures to protect your personal information from unauthorized access, disclosure, alteration, or destruction. However, no method of data transmission over the internet or electronic storage is entirely secure. Therefore, we cannot guarantee its absolute security.
7. Children’s Privacy
Our website and services are not intended for children under the age of 13. We do not knowingly collect personal information from children. If you believe that a child has provided us with their personal information, please contact us, and we will take appropriate steps to delete the information.
8. Changes to this Privacy Policy
We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. We encourage you to review this Privacy Policy periodically for any updates.
9. Contact Us
If you have any questions or concerns about this Privacy Policy or our data practices, please contact us at autonomix@jtcir.com.
1. Acceptance of Terms
By accessing and using this website, you agree to abide by these Terms and Conditions, as well as any applicable laws and regulations. If you do not agree with these terms, please refrain from using this website.
2. Use of Content
All content on this website, including but not limited to text, images, graphics, videos, and logos, is the property of Autonomix or its affiliates and is protected by intellectual property laws. You may not reproduce, distribute, or display any content without prior written permission.
3. User Conduct
You agree not to engage in any of the following activities while using this website:
4. Privacy Policy
Your use of this website is also governed by our Privacy Policy, which outlines how we collect, use, and protect your personal information. By using this website, you consent to the practices described in our Privacy Policy.
5. Links to Third-Party Websites
This website may contain links to third-party websites. These links are provided for convenience only, and Autonomix does not endorse or assume responsibility for the content or practices of these websites. Accessing third-party websites is at your own risk.
6. Disclaimer of Warranties
This website is provided “as is,” without any warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, or non-infringement. Autonomix does not warrant that the website will be error-free or uninterrupted.
7. Limitation of Liability
To the fullest extent permitted by law, Autonomix shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising out of or related to your use of this website. This includes but is not limited to any loss of data or profits.
8. Governing Law
These Terms and Conditions shall be governed by and construed in accordance with the laws of the United States. Any disputes arising under these terms shall be subject to the exclusive jurisdiction of the courts in the United States.
9. Changes to Terms and Conditions
Autonomix reserves the right to modify or revise these Terms and Conditions at any time. It is your responsibility to review this page periodically for updates. Your continued use of the website after any changes signifies your acceptance of the revised terms.
10. Contact Information
If you have any questions or concerns about these Terms and Conditions, please contact us at autonomix@jtcir.com.